Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Avenue Therapeutics Inc ATXI

Healthcare Drug Manufacturers - Specialty & Generic
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is developing three assets including AJ201, an asset for spinal and bulbar muscular atrophy; BAER-101, an oral small molecule selective Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAA a2, a3) receptor positive... see more

Recent & Breaking News (NDAQ:ATXI)

Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire August 14, 2023

Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire August 10, 2023

Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study

GlobeNewswire August 1, 2023

Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)

GlobeNewswire July 27, 2023

Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol

GlobeNewswire July 25, 2023

Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire May 15, 2023

Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

GlobeNewswire May 12, 2023

Avenue Therapeutics to Present at Aegis Capital Virtual Conference

GlobeNewswire April 27, 2023

Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol

GlobeNewswire April 17, 2023

Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire March 30, 2023

Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire March 30, 2023

Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates

GlobeNewswire March 8, 2023

Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy

GlobeNewswire March 2, 2023

Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)

Accesswire January 31, 2023

Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement

GlobeNewswire January 31, 2023

Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules

GlobeNewswire January 27, 2023

Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

GlobeNewswire November 10, 2022

Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders

GlobeNewswire November 8, 2022

Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI)

Accesswire October 12, 2022

Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering

GlobeNewswire October 11, 2022